Thursday, 6 May 2010
At the Annual General Meeting of Galenica Ltd., the shareholders approved all the proposals submitted by the Board of Directors. As a result, two new members were elected to the Board of Directors: Prof. Dr. Michel Burnier (CHUV, Lausanne) and Dr. Hans Peter Frick (General Counsel, Nestlé), both for a three-year period of office. The remuneration report was also almost unanimously approved.
The 82nd Annual General Meeting of Galenica Ltd. held today in Bern was attended by 424 shareholders representing in total 71% of the registered voting shares of Galenica Ltd.
The shareholders were informed that growth prospects for the new drug Ferinject® are confirmed. Galenica has therefore increased the operative expenditures for clinical studies in various indications and for the expansion of sales organisations in Europe in order to take full advantage of this potential.
The shareholders supported the proposals of the Board of Directors on all items on the agenda: The General Meeting approved the Annual Reports and the Financial Statements for 2009 for Galenica Ltd. and the Galenica Group and gave discharge to the members of the Board and the Corporate Executive Committee for the financial year 2009. The remuneration report, which was submitted for an advisory vote to the shareholders for the third time, was also almost unanimously approved.
Kurt W. Briner and This E. Schneider were each re-elected for a further three-year period of office. Carl M. Meyer, who has rendered great service to the company, has reached the age limit and left the Board of Directors. Two new members were proposed to the General Meeting for election to the Board of Directors: Prof. Michel Burnier, lecturer at the University of Lausanne’s Faculty of Biology and Medicine and Head of the Division of Nephrology and Hypertension at the Centre Hospitalier Universitaire Vaudois (CHUV), and Dr. Hans Peter Frick, Group General Counsel at Nestlé. Both were elected for a three-year period of office.
Furthermore, the shareholders approved amendments to the Articles of Incorporation. These amendments were particularly necessary to extend the period during which the authorised share capital can be increased and in order to comply with various changes in the law. The dividend of CHF 7.50 (+7.1%, prior year: CHF 7.00) proposed by the Board was also approved and will be paid to the shareholders on 17 May 2010.
The next Annual General Meeting of Galenica Ltd. will take place on 5 May 2011.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Wednesday, 1 December 2010
Tuesday, 28 September 2010
Friday, 17 September 2010
Tuesday, 17 August 2010